Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9P2R7

UPID:
SUCB1_HUMAN

ALTERNATIVE NAMES:
ATP-specific succinyl-CoA synthetase subunit beta; Succinyl-CoA synthetase beta-A chain

ALTERNATIVE UPACC:
Q9P2R7; B2RDE7; O95194; Q5T9Q4; Q5T9Q6; Q9NV21; Q9NVP7

BACKGROUND:
Succinyl-CoA synthetase beta-A chain, integral to the citric acid cycle, facilitates the synthesis of ATP from succinyl-CoA. This process is essential for energy production in cells. The enzyme's beta subunit ensures specificity for the nucleotide involved and the binding of the succinate substrate, playing a critical role in metabolic pathways.

THERAPEUTIC SIGNIFICANCE:
Linked to Mitochondrial DNA depletion syndrome 5, characterized by a range of neurological and metabolic abnormalities, the Succinyl-CoA synthetase beta-A chain's dysfunction underscores its therapeutic potential. Exploring its function could lead to novel treatments for mitochondrial disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.